3 Result: Seagen
Momentum Builds: Bladder Cancer Trial Data Boost Seagen
September 22nd, 2023
Astellas Pharma Inc. and Seagen Inc. (Nasdaq: SGEN) have reported promising results from the Phase 3 EV-302 clinical trial (KEYNOTE-A39) for PADCEV (enfortumab vedotin-ejfv) combined with Merck & Co., Inc.'s (NYSE: MRK) KEYTRUDA (pembrolizumab) versu. Read more
Seagen and Genmab: Breakthrough Cervical Cancer Trial Outcome
September 04th, 2023
Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) have reported a significant breakthrough in the Phase 3 innovaTV 301 global trial for recurrent or metastatic cervical cancer. Patients treated with TIVDAK (tisotumab vedotin-tftv) showed an im. Read more
Breaking: FTC Seeks More Info on Pfizer's Seagen Merger Plan
July 15th, 2023
Seagen Inc. (Nasdaq: SGEN) and Pfizer Inc. (NYSE: PFE) have encountered a regulatory hurdle in their planned merger. According to a regulatory filing with the SEC, both companies received a Second Request from the Federal Trade Commission (FTC) on Ju. Read more
Want To Find Some News?
News By Industries
Recent Post
-
October 29th, 2026
Treasury Sanctions Facilitators of DPRK IT Worker Fraud Targeting U.S. Businesses
October 28th, 2026Treasury Sanctions Rwandan Ministry of Defence and Financial Institution Supporting M23
October 28th, 2026October 26th, 2026FAA Releases Draft Design Standards for Vertical Flight Facilities
October 22nd, 2026
Member Login